# GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)

> **NCT00373685** · PHASE4 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 8067 (actual)

## Conditions studied

- Osteoarthritis

## Interventions

- **DRUG:** Celecoxib
- **DRUG:** Any commercially available NSAID with the indication for osteoarthritis

## Key facts

- **NCT ID:** NCT00373685
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 8067 (ACTUAL)
- **Last updated:** 2021-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00373685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00373685, "GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00373685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*